A5073861604- Pharmaceutical Practices and Patient Outcomes
- Sarcoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Bladder and Urothelial Cancer Treatments
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Pharmacovigilance and Adverse Drug Reactions
- Vascular Tumors and Angiosarcomas
- Renal cell carcinoma treatment
- Healthcare Systems and Practices
- Multiple and Secondary Primary Cancers
- Estrogen and related hormone effects
- Ferroptosis and cancer prognosis
- Health, Medicine and Society
- Safe Handling of Antineoplastic Drugs
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Sympathectomy and Hyperhidrosis Treatments
- Cardiac tumors and thrombi
- CAR-T cell therapy research
- Delphi Technique in Research
- Chemotherapy-related skin toxicity
Institut Bergonié
2015-2024
Université de Bordeaux
2019
Institut Claudius Regaud
2007-2013
Centre Léon Bérard
2013
Argonne National Laboratory
2009
Inserm
2007-2008
Université Toulouse III - Paul Sabatier
2007
The aim of this study was to assess the efficacy neoadjuvant anastrozole and fulvestrant treatment large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, identify genomic changes occurring after treatment. One hundred twenty post-menopausal patients were randomised receive 1 mg (61 patients) 500 (59 6 months. Genomic DNA copy number profiles generated a subgroup 20 before A total 108 evaluable 118 toxicity. objective...
Bladder cancer is the 7th cause of death from in men and 10th women. Metastatic patients have a poor prognosis with median overall survival 14 months. Until recently, vinflunine was only second-line chemotherapy available for who relapse. Deregulation PI3K/AKT/mTOR pathway observed more than 40% bladder tumors suggested use mTOR as target treatment urothelial cancers. This trial assessed efficacy temsirolimus homogenous cohort recurrent or metastatic following first-line chemotherapy....
Rho GTPases have been implicated in the control of several cellular functions, including regulation actin cytoskeleton, cell proliferation, and oncogenesis. Unlike RhoA RhoC, RhoB localizes part to endosomes controls endocytic trafficking. Using a yeast two-hybrid screen glutathione S-transferase pulldown assay, we identified LC2, light chain microtubule-associated protein MAP1A, as novel binding partner for RhoB. GTP 18-amino acid C-terminal hypervariable domain are critical its MAP1A/LC2....
This study aims to investigate the impact of medication reconciliation (MR) conducted by pharmacists before patient enrollment and initiation investigational treatments. By implementing MR, primary objective is evaluate extent which inclusion patients with prohibited or not recommended concomitant medications in clinical trials can be significantly reduced.
Abstract Purpose To improve the quality of care for patients with breast cancer, an analysis health-care pathway, considering feedback from both practitioners (HCPs) and patients, is needed. Methods Between 2020 2022, we conducted a survey at French cancer centers analyzed information questionnaires completed by HCPs patients. We collected on center organization, diagnostic processes, treatment decisions modalities, supportive care, patient advocacy groups, work issues. Results Twenty-three...
TPS11587 Background: PD-L1 is expressed in soft tissue sarcomas (STS) but PD-1 inhibition alone has limited activity. This primary resistance may partly be explained by IDO pathway activation. Epigenetics modifications have also been recognized as mechanisms of to inhibition. We hypothesized that the association MK3475 (PZ) + mCP, either or with inhibitor Epacadostat (EP), TLR4 agonist G100 EZH2 Tazemetostat (TZ) could a synergistic activity good safety pts advanced STS, focus on...
TPS2703 Background: Recent studies have shown that genetic depletion of EZH2 in Tregs (using FoxP3creEZH2fl/fl mice) and pharmacological inhibition elicits phenotypic functional alterations Tregs, leading to an effector-like T cell profile. Further, enhances the cytotoxicity human Teffs vitro proportion tumor-infiltrating cytotoxic cells vivo murine models. It has been immune checkpoint (ICI) increases expression across various tumor types increased inversely correlate with clinical outcome....
304 Background: Bladder cancer is the 7th cause of death from in men and 10th women. For metastatic patients, prognosis poor with a median overall survival 15 months that remained unchanged for past years. No standard second-line chemotherapy available patients who relapse. Acquired mutations leading to deregulation PI3K/AKT/mTOR pathway have been reported more than 40% bladder cancers suggesting use mTOR (mammalian target rapamycin) signalling as an attractive treatment urothelial tumors....
Abstract Purpose: Biophysical and analytical assays have demonstrated the physical chemical stabilities of an admixture pertuzumab trastuzumab co-administered via a single infusion bag. Few data are available concerning use this practice in real life. We report safety bag for first-line treatment human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods: A cancer registry was used to identify all patients with HER2-positive In cycle 1, received intravenous loading doses...